Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Inflammation and Immunity > Tumor and Transplant > Flashcards

Tumor and Transplant Flashcards

1
Q

Tumor and transplants - what is common

A

The immune response for the 2 are pretty similar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Ipillimumab

A

Anti CTLA4 antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Nivolumab

A

Anti PD-1 antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When is Nivolumab used

A

Non small cell lung carcinoma and melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adjuvents

A

Agents that cause inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Sipuleucal T

A

The idea over here is that patients with metastatic castrate resistant prostate cancer have their dendritic cells extracted from them, shipped to a company, the company incubates them in GM-CSF, exposes them to an antigen called the PAP (Prostate Acid Phosphatase). Then these dendritic cells are sent back and infused in the patient and this causes an immune response to develop against the cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bi specific antibodies

A

These promote tumor immunity. In this antibody we have different light chains and heavy chains linked together such that one half of the antibody targets the tumor cell whereas the other half targets the T cell (specific for CD3 protein or NK marker like CD16). This causes the tumor cells and T cells to come in close proximity promoting tumor destruction.

You can also have trispecific so the FC region can be made to bind to NK cells and the tumor cell can be made to be surrounded with NK cell and T cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Chimeric antigen

A

One of the problems when dealing with tumors is that tumors down regulate their MHC so the T cells cant identify them.

This problem can be solved by making single chain antibodies (scFv). Here the portion of the antibody that binds to antigen is fused with the zeta chain of the TCR. This whole complex is placed into the T cells to repalce TCR. This then allows the T cells to detect antigens without having to require MHC presentation and now they can go and kill cancer cells.

Very successful in lymphoma treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Syngenic

A

Genetically identical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Congenic

A

Identical except for one locus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Allogenic

A

Different members of the same species

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Xenogenic

A

Members of different species

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Autologous transplantation

A

Transplantation within the same individual like skin grafts, HSCTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Allotransplantation

A

Most common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Xenogenic transplantation

A

Xenografts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the antigen observed in organ transplant

A

MHC, there are minor histocompatibility complex - allelic forms of normal proteins that differ in people

17
Q

What are the mechanisms of organ rejection

A

Adaptive, T cells and antibodies

18
Q

What is the biochemical basis of transplant rejection

A

There is a change in the affinity of MHC-TCR interaciton these 2 interact more strongly now which leads to development of an immune response. Remember the low affinity model of thymic selection which requires that if T cells dont bind to MHC loosely so that they dont trigger an immune response

19
Q

What are the 2 ways body identifies the foreign organ after a transplant

A
  1. Direct allorecognition: T cells go into the transplant organ, recognizes the transplanted organ and mount an immune response towards it
  2. Indirect allorecogntion is when there is cross presentation so the APC goes into the transplant, engulfs one of the cells and presents the antigen to T cells. He called this process cross presentation.
20
Q

What 2 immune functions are significant in terms of cross presentation

A
  1. Viral infections

2. Tissue rejection

21
Q

How can we predict transplant rejection

A

Mixed lymphocyte reaction: Mix the T cells of the recipient with the irradiated donor cells (we need to kill the donor cells so they dont start an immune response). If the recipient T cells are activated then there will be T cell infiltration and proliferate which can be checked for.

22
Q

What are the 3 types of rejections

A
  1. Hyperacute
  2. Acute
  3. Chronic
23
Q

Hyperacute

A

Malpractice, very fast response.
The immune response is adaptive, however the immune response is pretty damn fast that suggests there are pre existing antibodies.
1. Antibodies could exist from prior trasnfusion
2. Activates compliment and blood clothing mechanisms

24
Q

Acute

A

CD8 T cell mediated:

  1. Targets graft or blood vessels within the graft
  2. Antibodies also contribute to vascular rejection, role of antibodies is unclear in chronic and acute
25
Q

Chronic

A

From hyperactue to chronic we move from more of a type II reactions to a type IV reaction.
So here the T cells kick in:
1. Th1 mediated response
2. Antibodies and compliment system activation, role is unclear
3. Progressive loss of graft tissue
4. Fibrosis and arteriosclerosis of graft tissue (narrowing of the vessels to the graft).

Chronic in inevitable, happens over the years.

26
Q

Therapy for graft rejection

A

Immunosuppression:

  1. GCs.
  2. Cyclosporin
  3. Mycophenolate
  4. Rapamycin
  5. Thymoglobulin - cocktail of antibodies, target T and B cell and also attacks the antibodies.
27
Q

What is HSC transplantation used for

A

Used for primary immunodeficiencies and after chemotherapy for cancer

28
Q

What markers does HSCs have

A

CD34

29
Q

Describe HSCs transfer

A
  1. Space created before injection - maybe by high dose chemotherapy
  2. Isolate CD34 cells
  3. Treat the donor with G-CSF so CD34 cells become immobilized into the blood, then we can harvest them from the blood
30
Q

Risks of HSC transplant

A
  1. Graft failure
  2. Delayed engraftment; hemorrhage and anemia
  3. Opportunistic infections - reactivation of CMV, EBV, bacterial pneumonias and fungal infections
  4. Tumor reoccurence
  5. GVHD - Graft versus Host disease, the major problem, mortality is 50%
31
Q

How do we consider the directions of immune response in solid tissue transplant and HSC transplant

A

In solid tissue transplant the recipient’s immune system attacks the graft whereas in HSC the donor’s immune system attack’s the body, this is called graft vs host disease.

When evaluating the MHC’s considering the directionality is critical

32
Q

Requirements for graft versus host disease (GVHD)

A

Billingham’s postulates:

  1. Graft must contain immunologically competent cells. There can be special circumstance where this has to be understood well as in liver trasnplants this can happen as live has many macrophages in there to protect it (kupfer cells)
  2. Recipients must have tissues and antigens that are not expressed in the donor
  3. Recipient must be not be able to mount an effective immune response to the graft to destroy the transplanted cells
33
Q

What are these relevant to

A

HSCT and blood products in infants, thats why the blood is irradiated before given to infants

34
Q

Categories of GvHD

A

Acute and Chronic

35
Q

Acute

A

Phase 1: We destroy the CD34 cells of the recipient to make room for the new CD34 cells to come in and thrive. in order to do this there is myloablative therapy given which is highly toxic and triggers release of cytokines such as TNF and IL-1

Phase 2: Some of the donor’s CD4 cells are also given to the recipient to prevent reactivation of EBV, CMV and prevent opportunistic infections even though these CD4 cells are going to cause GVHD.

Phase 3: The donor’s CTL, NK cells and monocytes respond to the cytokines and cause GVHD

36
Q

What is the time frame for acute and chronic

A

More than 100 days is chronic

37
Q

Chronic

A

3 phases:

  1. Progressive - continuation of GVHD
  2. Quiescent - presence of continued GVHD with previosuly resolved GVHD
  3. De novo - New onset of GVHD
38
Q

What is the MOA of chronic GVHD

A
  1. Th1 cell mediated immune response
  2. B cell are also involved.
  3. Organs involved are GI, Skin, thymus, BM, lung and bone
39
Q

Treatment for gvhd

A
  1. Steroids
  2. methotrexate
  3. cyclosporin
  4. mycophenylate
  5. Anti CD25 which is Daclizumab

Inflammation and Immunity (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions